Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Squamous Cell Carcinoma of Head and Neck 22Uterine Cervical Neoplasms 19Lung Neoplasms 19Small Cell Lung Carcinoma 16Oropharyngeal Neoplasms 14Ovarian Neoplasms 12Carcinoma 10Urinary Bladder Neoplasms 9Stomach Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Fallopian Tube Neoplasms 9Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Mesothelioma, Malignant 7Medulloblastoma 7Breast Neoplasms 7Adenocarcinoma of Lung 7Neuroblastoma 6Nasopharyngeal Carcinoma 6Gallbladder Neoplasms 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Lymphoid Interstitial Pneumonia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Platinum × Clear all
NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡